For close to two years, Sunday Riley management allegedly led a company-wide practice of posting glowing reviews of its products on Sephora.com without proper disclosures. The company is barred from repeating such conduct under terms reached with the FTC, but two dissenting commissioners say the settlement falls short of what’s needed to address a growing problem.
“Credibility is key to the reviews!” management at Sunday Riley Modern Skincare, LLC reminded employees repeatedly while instructing them on how to review the company's products positively on Sephora.com using fake accounts to hide their identities.
So says the US Federal Trade Commission in its complaint against the Houston, TX-based company, which has agreed to settle...
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
